阅读说明：本技术 禽戊型肝炎病毒orf2亚单位疫苗 (Avian hepatitis E virus ORF2 subunit vaccine ) 是由 赵鹏 赵慧 王一新 常爽 于 2021-11-16 设计创作，主要内容包括：本发明公开了一种禽戊型肝炎病毒ORF2亚单位疫苗,其包括第一重组蛋白和第二重组蛋白；所述第一重组蛋白的氨基酸序列如SEQ ID NO.1所示,所述第二重组蛋白的氨基酸序列如SEQ ID NO.2所示。本发明利用两株不同来源且差异较大的病毒,通过原核表达制备病毒的ORF2蛋白,将其混合制备成亚单位疫苗,解决了目前临床防治禽戊型肝炎病毒存在的困境,也进一步扩大了疫苗的抗体保护范围。(The invention discloses an avian hepatitis E virus ORF2 subunit vaccine, which comprises a first recombinant protein and a second recombinant protein; the amino acid sequence of the first recombinant protein is shown as SEQ ID NO.1, and the amino acid sequence of the second recombinant protein is shown as SEQ ID NO. 2. The invention utilizes two strains of viruses with different sources and larger difference to prepare the ORF2 protein of the virus through prokaryotic expression, and the ORF2 protein is mixed to prepare the subunit vaccine, thereby solving the dilemma of clinically preventing and treating the avian hepatitis E virus at present and further expanding the antibody protection range of the vaccine.)

1. An avian hepatitis E virus ORF2 subunit vaccine, characterized in that it comprises a first recombinant protein and a second recombinant protein;

the amino acid sequence of the first recombinant protein is shown as SEQ ID NO.1, and the amino acid sequence of the second recombinant protein is shown as SEQ ID NO. 2.

2. The avian hepatitis E virus ORF2 subunit vaccine of claim 1, wherein the weight ratio of the first recombinant protein to the second recombinant protein is 1: 1.

3. The avian hepatitis E virus ORF2 subunit vaccine of claim 1 or 2, wherein the avian hepatitis E virus ORF2 subunit vaccine further comprises an adjuvant.

4. The avian hepatitis E virus ORF2 subunit vaccine according to claim 3, wherein the adjuvant is one or more of a chemical adjuvant, a microbial adjuvant and a plant adjuvant.

5. The avian hepatitis E virus ORF2 subunit vaccine of claim 4, wherein the adjuvant is Freund's complete adjuvant or Freund's incomplete adjuvant.

6. The method for preparing the avian hepatitis E virus ORF2 subunit vaccine of any one of claims 1-5, characterized by comprising the steps of:

(1) uniformly mixing the first recombinant protein and the second recombinant protein according to the weight ratio of 1:1 to obtain an antigen composition;

(2) mixing the antigen composition with adjuvant, and emulsifying.

7. Use of the avian hepatitis E virus ORF2 subunit vaccine according to any one of claims 1 to 5 in the preparation of a product for the prevention or treatment of a disease caused by avian hepatitis E virus.

Technical Field

The invention relates to the technical field of genetic engineering, in particular to an avian hepatitis E virus ORF2 subunit vaccine.

Background

Avian hepatitis E (Avian hepatitis E) is caused by Avian Hepatitis E Virus (HEV). Mainly resulting in increased mortality and decreased laying rate of laying hens and broilers of 30-72 weeks of age. Clinical symptoms of sick chickens mainly include hepatosplenomegaly, hydroperitoneum, ovary degeneration and the like, and are widely prevalent and exist in chicken flocks worldwide at present. Both broilers and layers can be infected and are mainly transmitted through the fecal oral route.

Avian hepatitis E virus belongs to the family of hepatitis viruses, and belongs to the B genus of hepatitis E virus. The virus is a single-stranded positive-strand RNA virus without an envelope, and virus particles are spherical, have an icosahedral symmetric structure and are about 27-32 nm in diameter. The a-HEV genome is about 6.4-7.2kb and comprises three Open Reading Frames (ORFs) and two short non-coding regions at the 5 'and 3' ends, ORF1, ORF2 and ORF3 respectively. Among them, ORF2 has close relation with virus infection invading host cells, plays a role in the capsid protein assembly process, and is also a good epitope for preparing subunit vaccines. The isolated a-HEV worldwide mainly has 4 genotypes: genotype 1 in australia and korea, genotype 2 in the united states, genotype 3 in china and europe, genotype 4 in hungary (sridhareal, 2017). Research studies have shown that genotype 3 and genotype 4 are zoonotic pathogens, and genotype 1 and genotype 2 are mainly confined to humans, and have led to a large-scale outbreak of hepatitis e.

At present, an efficient in-vitro cell culture system for avian HEV does not exist, which seriously restricts the culture of viruses and the development of vaccines, so that no commercial inactivated vaccine or weak live vaccine is developed so far. Different from inactivated vaccines and virus vector vaccines, the recombinant protein subunit vaccine is prepared by expressing and purifying pathogen antigen protein in engineering cells in a genetic engineering mode and then preparing the vaccine. The vaccine developed by a new technical route can play a necessary alternative role in the absence of an effective virus culture system.

Patent CN110013549A discloses a subunit vaccine of hepatitis e, which is prepared by screening a strain of hepatitis e virus (QD07 strain) with good immunogenicity, obtaining a novel antigen protein of hepatitis e virus, and performing soluble expression in enterobacter coli. However, because of the high variability of avian HEV, the homology of different strains is low, and it is difficult to achieve a good protective effect by immunizing only a single vaccine.

Disclosure of Invention

In view of the prior art, the invention aims to provide an avian hepatitis E virus ORF2 subunit vaccine. The invention utilizes two strains of viruses with different sources and larger differences to prepare the ORF2 protein of the virus through prokaryotic expression, and the two strains of viruses are mixed to prepare the subunit vaccine, thereby solving the dilemma of clinically preventing and treating the avian hepatitis E virus at present and further expanding the antibody protection range of the vaccine.

In order to achieve the purpose, the invention adopts the following technical scheme:

in a first aspect of the invention, an avian hepatitis e virus ORF2 subunit vaccine is provided, which comprises a first recombinant protein and a second recombinant protein;

the amino acid sequence of the first recombinant protein is shown as SEQ ID NO.1, and the amino acid sequence of the second recombinant protein is shown as SEQ ID NO. 2.

Preferably, the weight ratio of the first recombinant protein to the second recombinant protein is 1: 1.

Further, the avian hepatitis E virus ORF2 subunit vaccine also comprises an adjuvant.

Preferably, the adjuvant is one or more of a chemical immune adjuvant, a microbial immune adjuvant and a plant immune adjuvant.

More preferably, the adjuvant is Freund's complete adjuvant or Freund's incomplete adjuvant.

In a second aspect of the present invention, there is provided a method for preparing the avian hepatitis e virus ORF2 subunit vaccine, comprising the following steps:

(1) uniformly mixing the first recombinant protein and the second recombinant protein according to the weight ratio of 1:1 to obtain an antigen composition;

(2) mixing the antigen composition with adjuvant, and emulsifying.

In a third aspect of the invention, the invention provides an application of the avian hepatitis E virus ORF2 subunit vaccine in preparation of a product for preventing or treating diseases caused by the avian hepatitis E virus.

The invention has the beneficial effects that:

the invention selects two strains of avian hepatitis E virus VaHEV strains and YT-aHEV strains with different sources and larger differences as templates for the first time, and carries out recombinant expression to obtain ORF2 recombinant protein; ORF2 recombinant protein of VaHEV and ORF2 recombinant protein of YT-aHEV are mixed to prepare the avian hepatitis E virus ORF2 subunit vaccine. The avian hepatitis E virus ORF2 subunit vaccine prepared by the invention effectively solves the dilemma existing in the clinical prevention and treatment of avian hepatitis E virus at present, and improves the antibody generation effect of the immunized organism.

Drawings

FIG. 1: dissecting and examining diseased chicken infected with VaHEV strain; in the figure, A is hepatomegaly; b, hepatorrhagia due to hemorrhage; and C, splenomegaly.

FIG. 2: expression and purification of ORF2 protein; in the figure:

a: ORF2 amplified gel electrophoretogram; m is marker; 1,2: YT-aHEV ORF2 amplified fragment: 3,4: VaHEV ORF2 amplified fragment;

b: the enzyme digestion fragment of ORF2 recombinant plasmid; m is marker; 1, YT-aHEV ORF2 recombinant plasmid and PMD18-T vector after EcoR I and Xhol I enzyme digestion;

c: ORF2 protein gel SDS-PAGE result picture; m: marker; 1: the supernatant of VaHEV ORF 2; 2: VaHEV ORF2 inclusion bodies; 3, supernatant of YT-aHEV ORF 2; 4: YT-aHEV ORF2 inclusion bodies;

d: YT-aHEV ORF2 protein purification map; m is marker; 1.2.3, eluent; 4.5.6: washing liquid; 7.8.9.10: loading and flowing through liquid; the red frame is a target strip.

FIG. 3: indirect immunofluorescence detection results of protein expression conditions in LMH cells infected with YT-aHEV; 50-fold dilution of serum antibody of experimental chicken (left); chicken serum antibodies were diluted 100-fold (right).

Detailed Description

It should be noted that the following detailed description is exemplary and is intended to provide further explanation of the disclosure. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs.

As introduced in the background art, because of the high variability of avian HEVs, the homology of different strains is low, and it is difficult to achieve a good protection effect by immunizing only a single vaccine.

Based on the method, two strains of avian hepatitis E virus with different sources and larger difference are selected and mixed to prepare the subunit vaccine. The vaccine not only solves the blank of the avian hepatitis E vaccine, but also further expands the antibody protection range of the vaccine.

The two avian hepatitis E viruses selected by the invention are respectively VaHEV strain and YT-aHEV strain, wherein: the VaHEV strain is an avian HEV identified from a laying hen group in Hebei province, the whole genome sequence of the VaHEV strain is uploaded to NCBI GenBank, and the accession number is as follows: MG 976720.1; the genetic evolution analysis result based on the whole genome shows that the VaHEV is different from all currently known avian HEVs, and the VaHEV is in a separate evolutionary branch and belongs to a new subtype. The sick chicken shows that the egg laying peak period is obviously delayed, the egg laying rate is reduced by about 20 percent, and the embryo hatching rate of the sick chicken is reduced by more than 18 percent. The cesarean examination of the dead chicken can show splenomegaly and hepatohemorrhagic swelling (fig. 1).

The YT-aHEV strain is an avian HEV separated from a certain broiler breeder flock in Shandong province, belongs to the classical gene 3 type, and has completed whole genome sequencing and analysis (NCBI GenBank, accession number: MZ 736614.1). The related sick chicken flocks show typical hepatosplenomegaly and bleeding phenomena, and the peak period of the disease is about 20 weeks old.

The results of homology analysis of the two avian HEV strains from different sources show that the whole genome nucleotide sequence homology between the two strains is only 82.2%, the nucleotide sequence homology between the three ORFs is 82.3%, 81.7% and 85.1%, and the amino acid sequence homology is 86.3%, 90.9% and 72.4%.

The invention takes YT-aHEV broiler strain and VaHEV laying hen strain as templates, designs primers of ORF2 fragments, carries out amplification and recombinant protein expression, mixes ORF2 recombinant protein of VaHEV and ORF2 recombinant protein of YT-aHEV, and prepares the avian hepatitis E virus ORF2 subunit vaccine.

In order to make the technical solutions of the present application more clearly understood by those skilled in the art, the technical solutions of the present application will be described in detail below with reference to specific embodiments.

The test materials used in the examples of the present invention are all conventional in the art and commercially available.

Example 1: preparation of recombinant proteins

Aiming at strain sequences of VaHEV (laying hen source) and YT-aHEV (broiler chicken source), amplification primers of ORF2 are respectively designed. Wherein, the upstream primer sequence and the downstream primer sequence corresponding to the VaHEV strain are respectively as follows:

Va-ORF2-F：5’-GGATTCATGTCGCTGCGTGGATTGCTG-3’；(SEQ ID NO.3)

Va-ORF2-R：5’-CTCGAGTTAGGGTGGTGAGGGGAATGT-3’。(SEQ ID NO.4)

the upstream primer sequence and the downstream primer sequence corresponding to YT-aHEV are respectively as follows:

YT-ORF2-F：5’-GGATTCATGTCGCTGCGTGGATTGCTG-3’；(SEQ ID NO.5)

YT-ORF2-R：5’-CTCGAGTTAGGGTGGTGAGGGAAATGT-3’。(SEQ ID NO.6)

the amplification length of the Va-ORF2-F, Va-ORF2-R primer is 1818bp, and the sequence of the primer is shown as SEQ ID NO. 7; the amplification length of the YT-ORF2-F, YT-ORF2-R primer is 1821bp, and the sequence of the primer is shown as SEQ ID NO. 8.

Va-HEV strain and YT-aHEV strain whole genome plasmids are respectively used as templates, Va-ORF2-F, Va-ORF2-R, YT-ORF2-F, YT-ORF2-R is used as primers to prepare a PCR system, and the reaction conditions are that the pre-denaturation is carried out for 5min at 95 ℃, the denaturation is carried out for 30s at 95 ℃, the annealing is carried out for 30s at 55 ℃, and the extension is carried out for 2min at 72 ℃. ORF2 gene fragment was amplified and the amplified product was analyzed by gel electrophoresis (FIG. 2, A). Cutting the amplified product with glue to recover target segment, connecting the recovered product with segment (figure 2, B) with correct enzyme digestion on P ET-32a (+) expression vector, transforming into host bacterium Trans5 alpha chemically competent cell, picking single colony, shaking the bacterium overnight, and carrying out PCR identification of bacterium liquid. The positive clones were sent to Biotech limited of Kyoto, Beijing for sequencing.

Inoculating the bacterial liquid with correct sequencing into 1.5ml liquid LB culture medium (containing100 ug/ml ampicillin), 37 deg.C, 220rpm, shake culturing overnight, adding the bacterial liquid into 200ml LB medium the next day, shake culturing at 37 deg.C for about 2h, and detecting A₆₀₀The OD value was about 0.8. Adding IPTG, continuing inducing for 6h by a shaker at 30 ℃, collecting thalli, ultrasonically crushing, centrifuging, retaining and dissolving, uniformly mixing 40 mu l of dissolving solution and 10 mu l of 5 Xloading buffer solution, boiling for 5min, rapidly cooling at-20 ℃, carrying out 10% SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) electrophoretic identification analysis, determining that an electrophoretic band is correct (figure 2, C), and purifying the target protein by a nickel column (figure 2, D).

The ORF2 recombinant protein of VaHEV and the ORF2 recombinant protein of YT-aHEV are prepared by the method respectively, wherein the amino acid sequence of the ORF2 recombinant protein of VaHEV is shown in SEQ ID NO. 1; the amino acid sequence of ORF2 recombinant protein of YT-aHEV is shown in SEQ ID NO. 2.

Example 2: preparation of avian hepatitis E virus ORF2 subunit vaccine

The ORF2 recombinant protein of VaHEV and the ORF2 recombinant protein of YT-aHEV purified in example 1 were quantified by BCA protein quantification, and the absorbance of the sample was measured at a wavelength of 562nm, and a standard curve was drawn to calculate the sample concentration. Mixing ORF2 recombinant protein of VaHEV and ORF2 recombinant protein of YT-aHEV according to a weight ratio of 1:1, and mixing the mixed protein and Freund's complete adjuvant according to a ratio of 1: mixing and emulsifying by 1 volume, and completely emulsifying the two by using a three-way injector (the immunogen is dripped into cold water for 20min, and the complete emulsification is obtained without diffusion). Storing at 2-8 deg.C for use.

Comparative example 1:

the recombinant ORF2 protein of YT-aHEV prepared in example 1 was mixed with freund's complete adjuvant according to 1:1 volume of the mixed emulsion, wherein the weight of ORF2 recombinant protein of YT-aHEV is the same as that of the recombinant protein mixed in the example 2, and the two are completely emulsified by a three-way injector (the immunogen is dripped into cold water, and the complete emulsification is obtained after 20min non-diffusion), so as to prepare the subunit vaccine A.

Comparative example 2:

ORF2 recombinant protein of VaHEV prepared in example 1 was mixed with freund's complete adjuvant according to 1:1 volume of the mixture, wherein the weight of ORF2 recombinant protein of VaHEV is the same as that of the recombinant protein mixed in example 2, and the two are completely emulsified by a three-way syringe (the immunogen is dripped into cold water, and the complete emulsification is obtained after 20min without diffusion), so as to prepare the subunit vaccine B.

Test example 1:

1 day old SPF chicks were randomly divided into 4 groups of 5 animals each, and 2 animals of the placebo group. The test 1 group is an immune subunit vaccine A, the test 2 group is an immune subunit vaccine B, and the test 3 group is an avian hepatitis E virus ORF2 subunit vaccine prepared in the immunization example 2; the blank control group was saline. The immunization test was performed by means of subcutaneous injection to the neck of the chicken, and the protein and adjuvant were subjected to 1:1 and mixing uniformly. And carrying out second immunization after two weeks after the first immunization is finished, and taking blood for standby one week after each immunization is finished. After the two immunizations, aHEV Antibody detection (kit used for Antibody detection: Big Liver and space Disease Antibody test kit; manufacturer: Biocheck; production series number: DRF070) was carried out on the preserved chicken serum by indirect ELISA, and the S/P value was calculated. An S/P value of more than 0.2 is judged to be positive.

The detection result of the ELISA kit shows that the ORF2 subunit vaccine immunized by the SPF chicken twice can generate antibodies; the avian hepatitis e virus ORF2 subunit vaccine prepared in example 2 had better effect in inducing antibody production than the subunit vaccine prepared using ORF2 recombinant protein of YT-aHEV alone and ORF2 recombinant protein of VaHEV alone (table 1).

In the test process, the physiological state of the chicken is normal, and the disease attack or death condition does not exist, which shows that the subunit vaccine prepared by the invention is safe to use.

Table 1: antibody detection results after immunization

Test example 2:

the expression of the protein in the LMH cells infected with YT-aHEV is detected by an indirect immunofluorescence method. The chicken serum collected after immunizing YT-aHEV ORF2 protein is used as a primary antibody, two different dilutions of 50X and 100X are respectively used, and a rabbit anti-chicken lgG antibody marked by FITC is used as a secondary antibody. The fluorescence intensity of aHEV upon infection with LMH cells indicates the presence or absence of protein expression, and specific green fluorescence of the expressed protein was found in LMH cells at 100 × dilution, indicating that ORF2 antibody was produced in chicken serum (fig. 3). Proved that after the YT-aHEV ORF2 protein is immunized, a specific antibody capable of recognizing virus can be generated.

The above description is only a preferred embodiment of the present application and is not intended to limit the present application, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, improvement and the like made within the spirit and principle of the present application shall be included in the protection scope of the present application.

SEQUENCE LISTING

<110> Shandong university of agriculture

<120> avian hepatitis E virus ORF2 subunit vaccine

<130> 2021

<160> 8

<170> PatentIn version 3.5

<210> 1

<211> 605

<212> PRT

<213> VaHEV ORF2

<400> 1

Met Ser Ser Arg Gly Leu Leu Leu Met Leu Ala Met Cys Cys Gly Val

1 5 10 15

Ser Arg Gly Ser Gln Ala Leu Pro Ala Arg Asp Trp Arg Gly Gln Pro

20 25 30

Arg Arg Asp Asn Ser Ala Gln Trp Ser Ala Gln Glu Arg Pro Glu Gly

35 40 45

Ala Val Gly Pro Ala Ala Ser Thr Asp Val Val Thr Ala Ala Gly Thr

50 55 60

Arg Thr Val Pro Asp Val Asp Gln Ala Gly Ala Val Leu Val Arg Gln

65 70 75 80

Tyr Asn Leu Val Thr Ser Pro Leu Gly Ser Ala Thr Leu Gly Ser Thr

85 90 95

Asn Ala Glu Leu Tyr Ala Ala Pro Val Ser Pro Leu Met Pro Leu Gln

100 105 110

Asp Gly Thr Thr Ser Asn Ile Met Ser Thr Glu Ser Ser Asn Tyr Ala

115 120 125

Gln Tyr Arg Val Arg Gly Leu Thr Val Arg Trp Arg Pro Val Val Pro

130 135 140

Asn Ala Val Gly Pro Phe Ser Ile Thr Met Ala Tyr Trp Pro Gln Thr

145 150 155 160

Thr Ser Thr Ala Thr Ser Ile Asp Met Asn Ser Ile Lys Ser Thr Asp

165 170 175

Val Arg Val Val Leu Gln Pro Gly Thr Ala Cys Leu Leu Thr Ile Pro

180 185 190

Pro Glu Arg Leu Asp Tyr Lys Asn Asn Gly Trp Arg Ser Val Glu Thr

195 200 205

Val Ser Val Pro Gln Glu Asp Ala Thr Ser Gly Met Leu Met Val Cys

210 215 220

Val His Gly Thr Pro Trp Asn Ser Tyr Thr Asn Thr Val Tyr Thr Ala

225 230 235 240

Pro Leu Gly Met Val Asp Phe Ala Ile Glu Leu Gln Leu Arg Asn Leu

245 250 255

Ser Pro Gly Asn Thr Tyr Ala Ser Val Ala Arg Val Lys Val Thr Ser

260 265 270

Pro His Thr Ile Lys Ala Asp Pro Thr Gly Ala Thr Ile Thr Thr Thr

275 280 285

Ala Ala Ala Arg Phe Met Ala Asp Val Arg Trp Gly Leu Gly Thr Ala

290 295 300

Asp Asp Gly Glu Ile Gly His Gly Ile Leu Gly Val Leu Phe Asn Leu

305 310 315 320

Ala Asp Thr Val Leu Gly Gly Leu Pro Ser Ala Leu Leu Ala Ala Ser

325 330 335

Gly Gln Tyr Met Tyr Gly Arg Pro Val Gly Asn Ala Asn Gly Glu Pro

340 345 350

Asp Val Lys Leu Tyr Met Ser Val Glu Asp Ala Val Asn Asp Lys Pro

355 360 365

Ile Met Val Pro His Asp Ile Asp Leu Gly Thr Ser Pro Val Thr Cys

370 375 380

Gln Asp Tyr Gly Asn Gln His Val Asp Asp Arg Pro Ser Pro Ala Pro

385 390 395 400

Ala Pro Asn Arg Ala Phe Gly Thr Leu Arg Ser Gly Asp Val Leu Arg

405 410 415

Ile Thr Gly Ser Met Gln Tyr Val Thr Lys Ala Glu Leu Leu Pro His

420 425 430

Ser Val Ser Gln Gly Tyr Phe Gly Ala Gly Asp Thr Met Met Val His

435 440 445

Asn Val Ile Thr Gly Val Arg Ala Pro Ala Ser Ser Val Glu Trp Thr

450 455 460

Lys Ala Thr Val Asp Gly Val Pro Val Lys Thr Val Asp Ala Ser Ser

465 470 475 480

Gly Ser Asn Ser Phe Ala Ala Leu Pro Ala Phe Gly Lys Pro Ala Val

485 490 495

Trp Glu Pro Gln Gly Ala Gly Tyr Phe Tyr Gln Tyr Asn Asn Thr His

500 505 510

Gln Glu Trp Ile Tyr Phe Leu Gln Asn Cys Ser Ser Val Val Trp Tyr

515 520 525

Ala Ser Thr Asn Met Leu Gly Gln Lys Ser Asp Thr Ser Ile Leu Leu

530 535 540

Glu Val Arg Pro Ile Gln Ala Ser Asp Gln Pro Trp Phe Leu Ala His

545 550 555 560

His Thr Gly Gly Asp Asp Cys Thr Thr Cys Leu Pro Leu Gly Leu Arg

565 570 575

Thr Cys Cys Arg Gln Ala Pro Glu Asp Gln Ser Pro Glu Thr Arg Arg

580 585 590

Leu Leu Asp Arg Leu Ser Lys Thr Phe Pro Ser Pro Pro

595 600 605

<210> 2

<211> 606

<212> PRT

<213> YT-aHEV ORF2

<400> 2

Met Ser Leu Arg Gly Leu Leu Leu Met Leu Ala Met Cys Cys Gly Val

1 5 10 15

Ser Arg Gly Ser Gln Thr Leu Pro Ala Gly Ser Arg Arg Gly Gln Arg

20 25 30

Arg Arg Asp Asn Pro Ala Gln Trp Ser Ala Gln Gln Arg Pro Glu Gly

35 40 45

Ala Val Gly Pro Ala Pro Leu Thr Asp Val Val Thr Ala Ala Gly Thr

50 55 60

Arg Thr Val Pro Asp Val Asp Gln Ala Gly Ala Val Leu Val Arg Gln

65 70 75 80

Tyr Asn Leu Val Thr Ser Pro Leu Gly Leu Ala Thr Leu Gly Ser Thr

85 90 95

Asn Ala Leu Leu Tyr Ala Ala Pro Val Ser Pro Leu Met Pro Leu Gln

100 105 110

Asp Gly Thr Thr Ser Asn Ile Met Ser Thr Glu Ser Ser Asn Tyr Ala

115 120 125

Gln Tyr Arg Val Gln Gly Leu Thr Val Arg Trp Arg Pro Val Val Pro

130 135 140

Asn Ala Val Gly Gly Ser Ser Ile Ser Met Ala Tyr Trp Pro Gln Thr

145 150 155 160

Thr Phe Tyr Pro His Ser Ile Asp Met Asn Ser Ile Thr Ser Thr Asp

165 170 175

Val Arg Val Val Leu Gln Pro Gly Ser Ala Gly Leu Leu Thr Ile Pro

180 185 190

His Glu Arg Leu Ala Tyr Lys Asn Asn Gly Trp Arg Ser Val Glu Thr

195 200 205

Val Ser Val Pro Gln Glu Asp Ala Thr Ser Gly Met Leu Met Val Cys

210 215 220

Val His Gly Thr Pro Trp Asn Ser Tyr Thr Asn Ser Val Cys Thr Gly

225 230 235 240

Pro Leu Gly Met Val Asp Phe Ala Ile Lys Leu Gln Leu Arg Asn Leu

245 250 255

Ser Pro Gly Asn Thr Asn Ala Arg Val Thr Arg Val Lys Val Thr Ala

260 265 270

Pro His Thr Ile Lys Ala Asp Pro Ser Gly Ala Thr Ile Thr Thr Ala

275 280 285

Ala Ala Ala Arg Phe Met Ala Asp Val Arg Trp Gly Leu Gly Val Ala

290 295 300

Glu Asp Gly Glu Ile Gly His Gly Ile Leu Gly Val Leu Phe Asn Leu

305 310 315 320

Ala Asp Thr Val Leu Gly Gly Leu Pro Ser Thr Leu Leu Arg Ala Ala

325 330 335

Ser Gly Gln Tyr Met Tyr Gly Arg Pro Val Gly Asn Ala Asn Gly Glu

340 345 350

Pro Glu Val Lys Leu Tyr Met Ser Val Glu Asp Ala Val Asn Asp Lys

355 360 365

Pro Ile Met Val Pro His Asp Ile Asp Leu Gly Thr Ser Thr Val Thr

370 375 380

Cys Gln Asp Tyr Gly Asn Gln His Val Asp Asp Arg Pro Ser Pro Ala

385 390 395 400

Pro Ala Pro Lys Arg Ala Leu Gly Thr Leu Arg Ser Gly Asp Val Leu

405 410 415

Arg Ile Thr Gly Ser Met Gln Tyr Val Thr Asn Ala Glu Leu Leu Pro

420 425 430

Gln Ser Val Ser Gln Gly Tyr Phe Gly Ala Gly Ser Thr Met Met Val

435 440 445

His Asn Leu Ile Thr Gly Val Arg Ala Pro Ala Ser Ser Val Asp Trp

450 455 460

Thr Lys Ala Thr Val Asp Gly Val Met Val Lys Thr Val Asp Ala Ser

465 470 475 480

Ser Gly Ser Asn Arg Phe Ala Ala Leu Pro Ala Phe Gly Lys Pro Ala

485 490 495

Val Trp Gly Pro Gln Gly Ala Gly Tyr Phe Tyr Gln Tyr Asn Ser Thr

500 505 510

His Gln Glu Trp Ile Tyr Phe Leu Gln Asn Gly Ser Ser Val Val Trp

515 520 525

Tyr Ala Tyr Thr Asn Met Leu Gly Gln Lys Ser Asp Thr Ser Ile Leu

530 535 540

Phe Glu Val Arg Pro Ile Gln Ala Ser Asp Gln Pro Trp Phe Leu Ala

545 550 555 560

His His Thr Gly Gly Asp Asp Cys Thr Thr Cys Leu Pro Leu Gly Leu

565 570 575

Arg Thr Cys Cys Arg Gln Ala Pro Glu Asp Gln Ser Pro Glu Thr Arg

580 585 590

Arg Leu Leu Asp Arg Leu Ser Arg Thr Phe Pro Ser Pro Pro

595 600 605

<210> 3

<211> 27

<212> DNA

<213> Artificial sequence

<400> 3

ggattcatgt cgctgcgtgg attgctg 27

<210> 4

<211> 27

<212> DNA

<213> Artificial sequence

<400> 4

ctcgagttag ggtggtgagg ggaatgt 27

<210> 5

<211> 27

<212> DNA

<213> Artificial sequence

<400> 5

ggattcatgt cgctgcgtgg attgctg 27

<210> 6

<211> 27

<212> DNA

<213> Artificial sequence

<400> 6

ctcgagttag ggtggtgagg gaaatgt 27

<210> 7

<211> 1818

<212> DNA

<213> VaHEV ORF2

<400> 7

atgtcgtcgc gtggattgct gctcatgctt gcaatgtgct gcggggtgtc aaggggctcc 60

caagcgctcc cagcccgaga ttggcgcggc caaccccgcc gcgacaactc agcacagtgg 120

agcgctcaag aacgccctga aggagccgtc ggcccagctg cttccactga tgttgtcacc 180

gcggcaggta ctcgcacggt accagatgta gatcaggccg gcgctgtgct ggtgcgccag 240

tacaatctag tgacgagtcc cctggggtcg gccaccctcg gtagcactaa tgctgaactt 300

tatgctgcac cggtttcgcc gttaatgcca cttcaggacg gcacgacgtc taatattatg 360

agcacggagt ctagcaacta tgcccagtac cgggtgcggg gtcttaccgt tcgatggcgt 420

ccggttgtgc cgaatgctgt cggtcccttt tccatcacca tggcttactg gcctcagaca 480

acgtccacgg ccacgagtat tgatatgaat tctatcaagt ccactgatgt tcgagttgtg 540

cttcagcccg gtaccgcgtg tttgctgacc ataccacctg agcgcctgga ctacaagaat 600

aatggttggc gctccgttga gactgtgtcg gtcccgcaag aagatgctac ctctggtatg 660

ctcatggttt gcgttcatgg gacaccctgg aacagttaca ccaatacagt ttataccgcg 720

ccgcttggga tggttgactt cgccatagag cttcagttgc ggaatctgtc acccggtaac 780

acttatgcca gtgttgcccg tgttaaggtt acgtccccac atactatcaa ggcggacccg 840

actggtgcta cgataactac tactgctgcg gcaaggttca tggcggatgt acgttggggt 900

ctgggtactg ctgatgatgg tgagattggc catggtatac taggtgtcct gtttaacctt 960

gctgatacag ttctcggcgg cctgccctca gcattgttgg cagccagtgg ccagtatatg 1020

tacggtcggc ccgttgggaa cgccaatggc gagccggatg tgaaacttta tatgtcagta 1080

gaggatgccg ttaatgataa gcctattatg gtcccacatg acatcgacct tggaactagc 1140

cctgtcactt gccaggatta tgggaaccag catgtggatg atcgcccgtc cccggctccg 1200

gcccccaatc gcgcttttgg tactctgcgg tcaggtgacg tgttgcgtat caccggctcg 1260

atgcagtatg tgactaaggc tgagctacta ccacatagtg tgtcgcaggg ctactttggg 1320

gccggtgaca ccatgatggt gcataatgtg attactggtg tgcgtgcccc tgctagttcg 1380

gtggagtgga ccaaggccac ggtggatgga gtcccggtca agaccgtcga tgctagttct 1440

ggaagcaaca gcttcgctgc actgcctgca tttggcaagc cagctgtttg ggagccccag 1500

ggcgctgggt acttctatca gtataacaac acccaccagg agtggatata tttccttcaa 1560

aattgcagct ctgtagtttg gtatgcatca accaacatgt tgggccagaa atctgataca 1620

tctatcctct tagaggtccg gccgatccag gctagtgatc agccttggtt tttggcacac 1680

catactggtg gcgatgattg caccacatgt ttgccgttgg gactaagaac atgttgccgt 1740

caggcaccag aggaccagtc accagagacg cgccggttgc tagaccgact tagtaagaca 1800

ttcccctcac caccttag 1818

<210> 8

<211> 1821

<212> DNA

<213> YT-aHEV ORF2

<400> 8

atgtcgctgc gtggattgct gctcatgctt gctatgtgct gcggggtgtc aaggggctcc 60

caaacgctcc cagcaggaag caggcgcggt caacgccgcc gtgacaaccc agcccagtgg 120

agcgctcaac aacgccccga aggagccgtc ggccccgccc ctcttaccga cgttgtcacc 180

gcggcaggta ctcgcacggt accagacgta gaccaggcag gggctgtgct ggtccgtcag 240

tataatctcg tgaccagccc gcttgggctg gccacccttg gcagcactaa tgccctgctt 300

tacgctgcgc cggtgtcacc gttaatgcca cttcaggacg gtacaacatc caatataatg 360

agcacggaat ctagcaatta tgctcagtac cgtgtgcagg gtctgaccgt tcgctggcgg 420

ccagttgtgc ctaatgcggt tggcgggtct tctattagca tggcttattg gccccaaaca 480

acattttacc cccacagcat agatatgaat tctattacat ccaccgacgt tcgtgtcgtg 540

cttcaaccag gttcggccgg cttgttaacc ataccgcatg aacgtttggc atacaagaat 600

aacggctggc ggtctgttga gacagtgtcg gtcccacaag aagacgcaac gtctggaatg 660

ctcatggttt gtgtccacgg tacaccctgg aacagttaca caaatagtgt gtgcaccggg 720

ccgctcggta tggttgactt tgctataaag cttcagttga ggaatttatc tcctggtaac 780

actaatgcta gggtcacccg tgtcaaggtg acagcccctc acactatcaa ggctgacccg 840

tcaggcgcca ccataacaac tgccgctgcg gctcggttta tggctgatgt gcgctggggt 900

ctgggtgtgg cggaagatgg tgagattggc catggtatcc ttggcgtcct gtttaatttg 960

gctgatacag tgttgggcgg cctcccgtcg acattgcttc gcgcggctag cggccagtat 1020

atgtacggcc gacctgttgg taacgctaat ggtgagcccg aagtgaaact gtatatgtcg 1080

gtagaggatg ctgtcaacga taagcccatc atggtccctc acgacattga cctcgggact 1140

agcactgtta cctgccagga ttatgggaat cagcatgttg atgaccgccc gtctccagcc 1200

ccggcaccga aacgcgcctt aggcacctta cggtccggag acgttttgcg catcaccggt 1260

tcgatgcagt acgtgactaa tgccgaactg ctgccgcaaa gtgtgtcgca gggctatttt 1320

ggggctggca gcaccatgat ggtgcataat ttaatcactg gtgtgcgtgc ccctgctagt 1380

tcagtcgact ggaccaaagc aacggtggat ggggttatgg tcaagactgt cgatgccagc 1440

tccggcagca acaggtttgc cgctttgccc gcgttcggta aaccagctgt gtggggacct 1500

cagggcgctg gctattttta ccagtataac agtacccatc aggagtggat ttacttcctt 1560

caaaatggga gttccgtggt ctggtacgca tacaccaata tgttgggcca gaagtctgac 1620

acgtcgatcc tctttgaggt acggccaatt caggctagcg accagccctg gtttctggcg 1680

catcataccg gcggtgatga ttgcaccacc tgtctaccgc tggggctcag gacatgctgc 1740

cgccaggcac ctgaagacca atcaccagag acgcgccggc ttctagaccg acttagtagg 1800

acattcccct caccacccta a 1821